Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS30000806HIVENSG00000088305.19protein_codingDNMT3BNoYes1789Q9UBC3
TVIS30053279HIVENSG00000088305.19protein_codingDNMT3BNoYes1789Q9UBC3
TVIS30053280HIVENSG00000088305.19protein_codingDNMT3BNoYes1789Q9UBC3
TVIS44030578HTLV-1ENSG00000088305.19protein_codingDNMT3BNoYes1789Q9UBC3
TVIS44027734HTLV-1ENSG00000088305.19protein_codingDNMT3BNoYes1789Q9UBC3
TCGA Plot Options
Drug Information
GeneDNMT3B
DrugBank IDDB01262
Drug NameDecitabine
Target IDBE0010009
UniProt IDQ9UBC3
Regulation Typeinhibitor
PubMed IDs17991895; 17023173; 29455551; 27330573
CitationsPalii SS, Van Emburgh BO, Sankpal UT, Brown KD, Robertson KD: DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol Cell Biol. 2008 Jan;28(2):752-71. Epub 2007 Nov 8.@@Oki Y, Aoki E, Issa JP: Decitabine--bedside to bench. Crit Rev Oncol Hematol. 2007 Feb;61(2):140-52. Epub 2006 Oct 4.@@Seelan RS, Mukhopadhyay P, Pisano MM, Greene RM: Effects of 5-Aza-2'-deoxycytidine (decitabine) on gene expression. Drug Metab Rev. 2018 May;50(2):193-207. doi: 10.1080/03602532.2018.1437446. Epub 2018 Feb 18.@@Diesch J, Zwick A, Garz AK, Palau A, Buschbeck M, Gotze KS: A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers. Clin Epigenetics. 2016 Jun 21;8:71. doi: 10.1186/s13148-016-0237-y. eCollection 2016.
GroupsApproved; Investigational
Direct ClassificationTriazinones
SMILESNC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1
Pathways
PharmGKBPA164749631
ChEMBLCHEMBL1201129